prohibited substance is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
=== Pharmacodynamics === Lemborexant is a dual antagonist of the orexin OX1 and OX2 receptors. It associates and dissociates from the orexin receptors more rapidly than certain other orexin receptor antagonists, such as suvorexant, and this may cause it to have a shorter duration of action.
=== Heart attacks === The relative risk of ischemic cardiac events seen in pre-approval trials of rosiglitazone was similar to that of comparable drugs, but there was increased LDL cholesterol, LDL/HDL cholesterol ratio, triglycerides and weight. In 2005, at the insistence of the World Health Organization, GSK performed a meta-analysis of all 37 trials involving use of rosiglitazone, finding a hazard ratio of 1.29 (0.99 to 1.89). In 2006 the GSK updated the analysis, now including 42 trials and showing a hazard ratio of 1.31 (1.01 to 1.70). A large observational study comparing patients treated with rosiglitizone with patients treated with other diabetes therapies was performed at the same time and found a relative risk of 0.93 (95% C.I. 0.8 to 1.1) for those treated with rosiglitazone. The information was passed to the FDA and posted on the company website, but not otherwise published. GSK provided these analyses to the FDA, but neither the company nor the FDA warned prescribers or patients of the hazard. According to the FDA, the Agency did not issue a safety bulletin because the results of the meta analysis conflicted with those of the observational study and with the results of the ADOPT trial. A meta-analysis in May 2007 reported the use of rosiglitazone was associated with a 1.4 fold increased risk of heart attack and a numerically higher (but non-significant) increase in risk of death from all cardiovascular diseases against control. It contained 42 trials of which 27 were unpublished.
The fruit, commonly known as açaí or açaí berry, is a small, round, black-purple drupe about 25 mm (1 in) in circumference, similar in appearance to a grape, but smaller and with less pulp and produced in branched panicles of 500 to 900 fruits. The exocarp of the ripe fruits is a deep purple color, or green, depending on the kind of açaí and its maturity. The mesocarp is pulpy and thin, with a consistent thickness of 1 mm (0.04 in) or less. It surrounds the voluminous and hard endocarp, which contains a single large seed about 7–10 mm (0.3–0.4 in) in diameter. The seed makes up about 60–80% of the fruit. The palm bears fruit year round but the berry cannot be harvested during the rainy season. The açaí palm is a light-loving plant, and fruit yields greatly decrease in amount and quality if the plants are shaded.
== Other business activity == Upon leaving Pepsi, Bello formed JoNa Ventures, a family investment vehicle that included among other endeavors investment and active involvement in Firefighter Brands, Soup Kitchen International, Eye and PresbyopiaTherapies and Beso Del Sol Sangria. With former NFL associates Bruce Burke and Peter French, Bello formed Firefighter Brands, a social enterprise intended to benefit local firefighting units with revenues generated from the sale of Firefighter Branded coffee, chips, chili's, trail mixes and energy drinks. The project was supported by a group of well to do and high-profile community minded investors but ultimately failed due to lack of cohesive co-operation among various firefighting entities. In 2005, Bello invested in and became chairman of Soup Kitchen International, a company he helped found that markets soups created by Al Yeganeh, the New York-based soup chef made famous as the "Soup Nazi" on the popular Seinfeld TV show, for retail stores, and developed franchised restaurants. In 2006 Bello became a general partner of Sherbrooke Capital, a venture capital firm that provides growth capital to early-stage health and wellness companies that led the $6.35 million equity-financing round for IZZE in early 2005. In the spring of 2006, Bello was appointed Chairman of the Board of the IZZE Beverage Company, a maker of sparkling juices. Izze was subsequently sold to PepsiCo for an undisclosed sum. Currently, Bello is in partnership with his college roommate and fraternity brother Dr. Lee Nordan serving as chairman of Eye Therapies.
=== Improving health care team outcomes === Undifferentiated connective tissue disease occurs for various reasons; underlying factors may affect several organs depending on individual sensitivity. Coordination of care between primary clinicians and experts (like rheumatologists) can help achieve optimal patient outcomes.
Sources: en.wikipedia.org
== History == Cannabinol (CBN) was the first cannabinoid isolated in the late 1800s, with its structure elucidated in the 1930s and synthesized by 1940. In 1942, Roger Adams discovered cannabidiol (CBD), followed by Raphael Mechoulam's identification of CBD stereochemistry in 1963 and THC stereochemistry in 1964. CBD and THC are produced independently from the precursor CBG, not via conversion.
=== Gene expression === PLP has been implicated in increasing or decreasing the expression of certain genes. Increased intracellular levels of the vitamin lead to a decrease in the transcription of glucocorticoids. Vitamin B6 deficiency leads to the increased gene expression of albumin mRNA. Also, PLP influences expression of glycoprotein IIb by interacting with various transcription factors; the result is inhibition of platelet aggregation.
Nickel(I) complexes are uncommon, but one example is the tetrahedral complex NiBr(PPh3)3. Many nickel(I) complexes have Ni–Ni bonding, such as the dark red diamagnetic K4[Ni2(CN)6] prepared by reduction of K2[Ni2(CN)6] with sodium amalgam. This compound is oxidized in water, liberating H2. It is thought that the nickel(I) oxidation state is important to nickel-containing enzymes, such as [NiFe]-hydrogenase, which catalyzes the reversible reduction of protons to H2.
== Career and research == In 1981, Busslinger joined the lab of Richard A. Flavell at the MRC Institute Mill Hill in London as a postdoctoral fellow. There, he discovered that a single nucleotide mutation in the first intron of the β-globin gene causes β+-thalassemia and that DNA methylation of promoter sequences prevents gene transcription. In 1983, Busslinger became a Group Leader at the Institute of Molecular Biology II of the University of Zurich. Here, he discovered a new set of histone genes of the sea urchin and identified a tissue-specific transcription factor (TSAP) as an essential regulator of these genes, which later turned out to be a member of the Paired box (Pax)-containing transcription factor family. In 1987, Max Birnstiel recruited Busslinger to join the newly founded Research Institute of Molecular Pathology (IMP) in Vienna, Austria, as one of the first Senior Scientists. In 1996, Busslinger was appointed Professor at the University of Vienna. In 2007, he became the IMP's Director of Academic Affairs and, in 2013, Scientific Deputy Director. At the IMP, Busslinger changed his research focus from sea urchin embryogenesis to B cell immunology, which was promoted by the identification of a B-cell-specific transcription factor as a mammalian homologue of the sea urchin regulator TSAP. Protein purification and sequencing identified the B-cell-specific transcription factor as Pax5, and gene inactivation in the mouse defined Pax5 an essential regulator of B cell development.
Sources: en.wikipedia.org
Venturing beyond Cumana, Humboldt and Bonpland received hospitality from local mulatto peasants, who were unfamiliar with their European origins but generous nonetheless. During one such excursion, they learned of a local laborer named Francisco Loyano, who had reportedly nursed a child with his own milk due to unusual lactation, a fact confirmed by local witnesses and Bonpland’s examination. By early September, acclimatized and prepared, Humboldt and Bonpland embarked on their first significant inland journey to the Cumanagoto tribe missions in the mountains south of Cumana. The challenging route led them through dense rainforest, across mountain streams, and along precipitous paths, where they marveled at the forest’s grandeur and the diversity of wildlife. The mission headquarters at Caripe, a cool, spring-fed location surrounded by mountains, became their base. Humboldt was surprised to find the Capuchin monks welcoming and tolerant, despite religious differences, and noted the presence of contemporary scientific texts among them. Daily life at Caripe was a blend of scientific work and cultural observation. Humboldt and Bonpland collected plants, studied the Cumanagoto language, and documented local customs, including the children’s consumption of large millipedes. Meals at the monastery reflected the monks’ sacrifices, as they often gave up their own rations for the guests. The soundscape was dominated by howler monkeys, especially during rain, and opportunities for astronomical observation were rare due to persistent mist.
The structure of the skin of the patagia and accessory areas for the patagia of a Ptychozoon kuhli, flying gecko, exhibiting the passive gliding mechanism consists of five layers; a layer of adipose tissue is surrounded by a layer of dermis on each side (ventral and dorsal) and a layer of epidermis is external to the two dermal layers. The distribution of the adipose tissue IS thickest close to the body wall. This thick layer of adipose tissue at close to the body wall is believed to provide a "safety factor" for the structural elements of the skin (i.e. collagen fibers) near the body wall. The thick layer of adipose tissue is more compliant than the structural elements of the body wall (i.e. ribs, muscles), therefore will more readily deform (absorb force) before the structural elements of the skin experience a force. The layer of adipose tissue also aids in the creation of the domed and cambered shape of the patagia. With regards to the structure of the dermal layer of the patagia, there is a thick layer of collagen fibers oriented parallel to the axis of the patagial ribs. These collagen fibers act as the structural support for the shape of the patagia, and provide the stiffness necessary to resist shape change. The most prominent features of the epidermal layer of the patagia are the scales. The morphology of the dorsal scales of the patagia change as a result of their functional role. A large portion of the dorsal scales of the patagia are arranged in regular rib-like pattern, which guide the flow of air and allow for the lizard to behave as an airfoil.
=== In Citrus === Extracts of unripe fruit from Asian cultivars of Citrus aurantium (commonly known as "bitter" orange), collected in China, were reported to contain synephrine levels of about 0.1–0.3%, or ~1–3 mg/g; Analysis of dried fruit of C. aurantium grown in Italy showed a concentration of synephrine of ~1 mg/g, with peel containing over three times more than the pulp. Sweet oranges of the Tarocco, Naveline and Navel varieties, bought on the Italian market, were found to contain ~13–34 μg/g (corresponding to 13–34 mg/kg) synephrine (with roughly equal concentrations in juice and separated pulp); from these results, it was calculated that eating one "average" Tarocco orange would result in the consumption of ~6 mg of synephrine. An analysis of 32 different orange "jams", originating mostly in the US and UK, but including samples from France, Italy, Spain, or Lebanon, showed synephrine levels ranging from 0.05 mg/g–0.0009 mg/g in those jams made from bitter oranges, and levels of 0.05 mg/g–0.006 mg/g of synephrine in jams made from sweet oranges. Synephrine has been found in marmalade made from Citrus unshiu (Satsuma mandarin) obtained in Japan, at a concentration of ~0.12 mg/g (or about 2.4 mg/20g serving). Most of the orange marmalades made in the US are produced using "sweet" oranges (C. sinensis), whereas "bitter" or Seville oranges (C. aurantium) are used for making the more traditional, bitterer marmalades in the United Kingdom. A sample of commercial Japanese C.
=== Future technology and research === Gene therapy is being explored as a treatment for missense mutations. This involves inserting the correct sequence of DNA into an incorrect gene. Artificial Intelligence programs, such as AlphaFold, are also being developed to predict the effect of missense mutations. Identifying potential deleterious mutations can assist with disease diagnosis and treatment.
planifolia seeds this way are Eulaema polychroma and Scaptotrigona subobscuripennis. Seeds being distributed by bees is a rare behavior and has only been documented in three species of tropical trees previously, the cadaghi (Corymbia torelliana), Coussapoa asperifolia subsp. magnifolia, and Zygia racemosa. Both rodents and marsupials are confirmed to consume fallen pods on the forest floor. Specific species observed eating the pods include Tome's spiny rat (Proechimys semispinosus) and the common opossum (Didelphis marsupialis). Further experiments by a team led by Dr. Adam Karremans showed that the seeds remained viable after being passed through the mammalian gut, but it did not increase or decrease germination significantly.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.